Proactive Investors - Run By Investors For Investors

Akorn shares slip after court rules that Fresenius can cancel its buyout of the generic drugmaker

Fresenius scrapped the merger after an investigation found Akorn had a history of fraudulent product data submissions
Scales of justice statue
The Delaware Supreme Court upheld a previous ruling in favor of Fresenius

Shares of Akorn Inc (NASDAQ:AKRX) slipped double digits after a judge ruled that German health care company Fresenius Medical Care (NYSE:FMS) had sufficient cause to end its $4.8 billion bid for the company.

Akorn shares plummeted about 28% to $4.05 in Monday afternoon trading while Fresenius shares were down nearly 9% to $35.73.

READ: Akorn's stock soars after FDA approves ANDA for eyelash treatment Bimatoprost

After the ink on the agreement had dried, an independent investigation revealed that generic drugmaker Akorn had a history of fraudulent product data submissions.

Fresenius, a provider of kidney dialysis care, sought to end the agreement.

Judge Travis Laster found in October that the termination of the merger was valid, citing Akorn’s compliance issues.

The judge also found that Akorn had failed to continue operating as normal after inking the deal.

Laster wrote that Akorn's "magnitude of inaccuracies would reasonably be expected to result in a material adverse effect," as per a Reuters report.

Akorn stood its ground and appealed the decision, claiming that it was a breach of a binding merger agreement and that Fresenius was suffering from buyer’s remorse.

The Delaware Supreme Court was not swayed, issuing an order that upheld Judge Laster’s findings, as per a Bloomberg report.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

 

 

View full FMS profile View Profile

Fresenius Medical Care Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use